EyePoint: Stock Takes Shellacking On Second Pivotal Eye Disease Study Miss (NASDAQ:EYPT)

Watertown biotech halves workforce after two late-stage trials miss their goals

EyePoint: Stock Takes Shellacking On Second Pivotal Eye Disease Study Miss (NASDAQ:EYPT)

EyePoint stock crashed 85% after Duravyu missed a Phase 3 wet AMD endpoint. Click here to read my most recent analysis of EYPT stock.

EyePoint to halve workforce after experimental drug fails second late-stage trial - Regional Media News

Oct 19 (Reuters) - EyePoint on Monday said it would cut about 53% of its workforce and stop studies of its experimental drug for an age-related vision disease after a second late-stage trial failed. Its shares tanked more than 75% in premarket trading.

Mass. biotech firm cuts 100 jobs after two late-stage trials miss their goals

A Watertown biotech is halving its workforce after two late-stage studies both missed their main goals.  EyePoint Inc. is calling it quits on development of a...

EYPT Stock Layoffs: What to Know About the Latest EyePoint Job Cuts

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

EyePoint will halve workforce, end pivotal wet AMD trials early following second fail

EyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shifting attention to the asset’s potential in diabetic macular edema.